Oculis Holding AG has signed an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics, ending their previous license agreement and associated royalties. The deal includes an upfront cash payment of $3.8 million and up to 2,050,000 Oculis shares, with closing expected by early 2027. This acquisition strengthens Oculis' position in neuro-ophthalmology, allowing it to fully control Privosegtor, a promising neuroprotective drug candidate advancing through key clinical trials for optic neuritis and multiple sclerosis. The move is expected to enhance Oculis' long-term value and development potential for Privosegtor and related assets.
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Academy Sports + Outdoors is celebrating Brooks Month from September 21 to October 18, highlighting its partnership with Brooks through a showcase of over 50 footwear styles, apparel, and accessories. The campaign includes expert guidance for runners...
Google is positioned as a comprehensive AI provider across hardware, software, cloud, and telecom sectors. Its backlog has increased tenfold in three years and now approaches four times its trailing twelve months revenue, supporting a 24% year-over-y...
